Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.

@article{CarbonellEstrany2010MotavizumabFP,
  title={Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.},
  author={Xavier Carbonell-Estrany and Eric A. F. Sim{\~o}es and Ron Dagan and Caroline Breese Hall and Brian J. Harris and Micki Hultquist and Edward M. Connor and Genevieve A. Losonsky},
  journal={Pediatrics},
  year={2010},
  volume={125 1},
  pages={e35-51}
}
OBJECTIVE Palivizumab reduces respiratory syncytial virus (RSV) hospitalization in children at high risk by approximately 50% compared with placebo. We compared the efficacy and safety of motavizumab, an investigational monoclonal antibody with enhanced anti-RSV activity in preclinical studies, with palivizumab. METHODS This randomized, double-blind, multinational, phase 3, noninferiority trial assessed safety and RSV hospitalization in 6635 preterm infants aged <or=6 months at enrollment or… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 57 extracted citations

Similar Papers

Loading similar papers…